Please assess the completion status of the following clinical trial:

Trial Title: Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with \>18 years of age;~* Symptoms of stable or unstable angina and/or presence of a positive functional test for ischemia;~* Presence of a single de novo target lesion located in a native coronary vessel suitable for percutaneous treatment with the study stents;~* Acceptable candidate for coronary artery bypass graft(CABG)surgery;~* The subject is willing to sign a written informed consent prior to procedure, and is willing to undergo ALL study protocol follow-ups,including angiographic, IVUS and OCT assessments.~* Single, de novo lesion~* Target lesion located in a major epicardial coronary vessel with reference of 2.5-3.5mm in diameter (by on-line QCA)~* Target lesions ≤19mm in length (by visual estimation) that can be treated (covered) by one single study stent (19 or 24mm in length);~* ≥50% and \<100% diameter stenosis;~* TIMI (Thrombolysis In Myocardial Infarction) flow grade ≥2.~Exclusion Criteria:~* Known hypersensitivity or contraindication to tacrolimus, heparin,any required medications including thienopyridines, and contrast media which cannot be adequately pre medicated;~* Patient is a female with childbearing potential;~* Pre-treatment of the target lesion with any devices other than balloon angioplasty;~* Previous brachytherapy in the target vessel;~* Presence of non-target vessel lesions which require staged procedure(s) \<30 days of the index procedure;~* Prior CABG surgery to target vessel;~* Previous percutaneous coronary intervention (PCI) or CABG surgery \<30 days to the index procedure date;~* Acute myocardial infarction \<3 days, with cardiac enzyme elevation including total creatine kinase (CK) \>2 times the upper normal limit value and/or CK-MB above the upper normal limit value within the past 72 hours;~* CK and/or CK-MB levels elevated above the upper normal limit value at the time of the index procedure;~* Documented left ventricular ejection fraction \<30%;~* Renal insufficiency determined by a baseline serum creatinine \>2.0 mg/dl;~* Thrombocytopenia with a baseline platelet count \<100,000 cells/mm3;~* Anemia with baseline hemoglobin \<10g/dL;~* Extensive peripheral vascular disease or extreme anticoagulation that precludes safe \>5 French sheath insertion;~* History of bleeding diathesis, coagulopathy, or refusal of blood transfusions;~* Patients has suffered a stroke, transient ischemic attack (TIA),or cerebrovascular accident (CVA) within the past 6 months;~* Significant gastrointestinal or genitourinary bleed within the past 6 months;~* Patient is a recipient of a heart transplant;~* Any elective surgical procedure is planned within 12 months of the index procedure;~* Known illness or any serious clinical condition with life expectancy \<2 years;~* Participation in the active or follow-up phase of any other clinicaltrial within 6 months;~* Impossibility to comply with anti-platelet therapy during the study clinical follow-up;~* Any impossibility to comply with all protocol follow-ups.~* Target lesion or vessel with angiographic evidence of moderate or severe calcification;~* Presence of severe tortuosity;~* Presence of severe angulation (\>60o);~* Presence of intraluminal thrombus;~* Target lesion involving a bifurcation (side branch ≥2.0mm);~* Target lesion located in the left main stem;~* Aorto-ostial lesion location;~* Target lesion involving a side branch with reference diameter≥2.0mm;~* Presence of a significant stenosis (\>40%) in the target vessel either proximal or distal to the target lesion that will be untreated;~* Previous placement of a stent within 10mm of the target lesion;~* Total occlusion (TIMI flow grade 0 or 1);~* Target lesion located in an arterial or vein graft;~* Target lesion due to in-stent restenosis;~* Coronary anatomy unsuitable for percutaneous treatment with implantation of the available study stents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues